Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma

Buitrago, Emiliano; Solé, María; Torbidoni, V.; Fandiño, Adriana; Asprea, Marcelo; Croxatto, J. Oscar; Chantada, Guillermo; Bramuglia, Guillermo F.; Schaiquevich, Paula

doi:10.1016/j.exer.2013.01.002

Cited by 44 publications

(35 citation statements)

References 20 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Following subconjunctival injections of 10 µg in mice and periocular injections of 1 mg in rabbits, there was no toxicity on fundoscopic exam nor on histopathology [28]. Furthermore, rabbit eyes injected with four weekly doses of either 0.5 or 5 µg topotecan showed no significant change in their ERG implicit times or amplitude compared with controls injected with saline [29]. With periocular injections in human patients, the only reported local toxicities occurred in the anterior segment, including conjunctival congestion and eyelid chemosis [30].…”

Section: Discussionmentioning

confidence: 93%

Electroretinogram Monitoring of Dose-Dependent Toxicity after Ophthalmic Artery Chemosurgery in Retinoblastoma Eyes: Six Year Review

et al. 2014

View full text Add to dashboard Cite

PurposeTo report electroretinogram responses of retinoblastoma children under anesthesia before and after treatment with chemotherapeutic drugs (melphalan, topotecan, carboplatin) delivery by ophthalmic artery chemosurgery (OAC).MethodsA cohort study of 81 patients with retinoblastoma treated with OAC. All patients treated with OAC at our center through May 2012 for whom the requisite ERG data were available are included in the analysis. This study recorded the ERG 30 Hz flicker amplitude response changes from baseline, at 3 and 12 months following OAC treatment completion. Both univariate and multivariate linear regression models were evaluated, with generalized estimating equations to correct for correlations within patients. Independent numerical variables included maximum doses and cumulative doses of melphalan, topotecan and carboplatin.ResultsBy univariate analysis, both melphalan and topotecan appear to be associated with changes in ERG amplitude at both 3 and 12 months; but for the most part, these changes are minimal and likely clinically insignificant. By multivariate analysis, maximum and cumulative melphalan have a modest, temporary effect on the ERG amplitude change, which is apparent at 3 months but no longer evident at 12 months after completing treatment. By multivariate analysis, topotecan and carboplatin do not appear to adversely effect the change in ERG response.ConclusionMelphalan has the strongest, and carboplatin the weakest association with reduction in ERG response amplitudes; but for the most part, these changes are minimal and likely clinically insignificant. These conclusions apply only over the dose ranges used here, and should be applied with caution.

show abstract

Section: Discussionmentioning

confidence: 93%

Electroretinogram Monitoring of Dose-Dependent Toxicity after Ophthalmic Artery Chemosurgery in Retinoblastoma Eyes: Six Year Review

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Topotecan as a periocular injection for retinoblastoma has also been well-tolerated, with only minimal conjunctival congestion and eyelid chemosis, and negligible systemic complications 14. Rabbit eyes injected with four-weekly doses of up to 5 µg/0.1 mL of intravitreal topotecan showed no significant retinal or systemic toxicity 25. Ghassemi et al 16 used intravitreal topotecan at a dose of 8–20 µg/0.04 mL in combination with melphalan for vitreous seeds, and observed no changes on ERG.…”

Section: Discussionmentioning

confidence: 99%

Intravitreal topotecan in the management of refractory and recurrent vitreous seeds in retinoblastoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The addition of topotecan to melphalan has been evaluated in rabbits and found to reach bioavailable levels with minimal toxicity [71]. Ghassemi et al [72 && ] studied the addition of intravitreal topotecan with melphalan in humans and noted that this lead to complete vitreous seed control with a remarkable one or two injections, without the need for the standard six injections.…”

Section: When To Use Intravitreal Chemotherapymentioning

confidence: 99%

Targeted retinoblastoma management

Shields

Lally

Leahey

et al. 2014

Current Opinion in Ophthalmology

144

View full text Add to dashboard Cite

show abstract

Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma

Cited by 44 publications

References 20 publications

Electroretinogram Monitoring of Dose-Dependent Toxicity after Ophthalmic Artery Chemosurgery in Retinoblastoma Eyes: Six Year Review

Electroretinogram Monitoring of Dose-Dependent Toxicity after Ophthalmic Artery Chemosurgery in Retinoblastoma Eyes: Six Year Review

Intravitreal topotecan in the management of refractory and recurrent vitreous seeds in retinoblastoma

Targeted retinoblastoma management

Contact Info

Product

Resources

About